<DOC>
	<DOCNO>NCT01123460</DOCNO>
	<brief_summary>RATIONALE : Studying sample blood laboratory patient receive erlotinib hydrochloride may help doctor learn effect erlotinib hydrochloride cell . It may also help doctor understand well patient respond treatment . PURPOSE : This research study study biomarkers predict response patient non-small cell lung cancer previously treat erlotinib hydrochloride .</brief_summary>
	<brief_title>Biomarkers Predicting Response Patients With Non-Small Cell Lung Cancer Previously Treated With Erlotinib Hydrochloride</brief_title>
	<detailed_description>OBJECTIVES : - To evaluate whether serum NGAL , MMP-9 , NGAL/MMP-9 complex , soluble E-cadherin utilized biomarkers predict response patient non-small cell lung cancer treat erlotinib hydrochloride . OUTLINE : Serum sample analyze NGAL , MMP-9 , NGAL/MMP-9 , soluble E-cadherin ELISA Luminex assay .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis nonsmall cell lung cancer Received erlotinib hydrochloride clinical trial ECOGE3503 PATIENT CHARACTERISTICS : Not specify PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>non-small cell lung cancer</keyword>
</DOC>